Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.
Steady: 1 development in the last 24 hours, 1 in the last 7 days
Updated yesterday
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Syndax secured FDA approvals and named Aaron as its new Chief Financial Officer.1 source
- FDA granted Priority Review for Syndax's sNDA on June 25, 2025.Sub-event
Syndax uses LinkedIn for company communication regarding its FDA-approved pipeline.1 source
Keep exploring
The entities involved
- FDA
-
Syndax Pharmaceuticals
business
-
LinkedIn
American social networking website for people in professional occupations
Related events
- Syndax Pharmaceuticals presented data at EHA Congress and is seeking successful regulatory approval for its drug pipeline.
- Syndax Pharmaceuticals management attended conferences in Boston, London, and New York on October 30, 2026.
- Research advances have led to the approval of new therapies by the FDA.
- Syndax Pharmaceuticals received an award from the Galien Foundation on October 30, 2026.
- Bit Digital stakes Ethereum to generate protocol-native yield and uses LinkedIn for investor information.
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmac
- GlobeNewswireSyndax Announces Participation in September Investor Conferences NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advanc
- GlobeNewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmace
- GlobeNewswireSyndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a co
- Unknown outlet